We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pine Bark Reduces Osteoarthritis and Lowers Joint Pain

By Biotechdaily staff writers
Posted on 08 May 2008
An antioxidant plant extract has been shown to reduce all osteoarthritis (OA) symptoms by 56%, reducing the need for pain medication, and thus improving the gastrointestinal complications resulting from the drugs.

Researchers at the Chieti-Pescara University (Italy) conducted a randomized, double blind, placebo-controlled study of 156 patients with OA of the knee. More...
Patients were administered 100 mg Pycnogenol or placebo, daily for three months. Symptoms were evaluated by WOMAC (Western Ontario and McMaster Universities) index scores and mobility by recording their walking performance on a treadmill. Patients were permitted to continue taking their choice of pain medication provided they recorded every tablet in a diary for later evaluation. Foot volume was measured by the water-displacement method to evaluate foot edema in a randomly selected subgroup of subjects within the two treatment groups. Patients were allowed to use their regular dosage of non-steroid anti-inflammatory drugs (NSAIDs).

The results showed that after three months, scores for pain dropped significantly for the Pycnogenol treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53%. The scores for physical function were reduced by 57% in the Pycnogenol group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol treatment by 56%. Overall wellbeing of patients (emotional function) was significantly enhanced with the Pycnogenol group compared to the placebo group (64% vs. 15%). Results of exercise tests on the treadmill demonstrated an increased performance after three months of Pycnogenol treatment. After the three months, edema decreased in 79% of the Pycnogenol patients and only 1% in placebo-treated patients. NSAID usage dropped by 58% during treatment with Pycnogenol, but only by 1% in treatment with the placebo. The study was published in the April 2008 edition of the journal Phytotherapy Research.

"Pycnogenol seemed a natural fit for this study,” said lead author Gianni Belcaro, M.D. "There are a few main components contributing to the clinical picture of treatment management in osteoarthritis: inflammation causing a progression in the disease, alteration of fatigue resistance and muscular performance - reversing and blocking the vascular problems associated to altered mobility. Theoretically, a treatment with a compound specifically active on all those aspects could be highly effective, which is why we chose Pycnogenol.”

Pycnogenol is a natural antioxidant plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids, and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient.


Related Links:
Chieti-Pescara University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.